NZNadim Zaidan

Nadim Zaidan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nadim Zaidan has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reclassifying Aortic Stenosis Severity: Combined Energy Loss Index and Global Longitudinal Strain Assessment Identifies Subgroups with Differential Myocardial Function and May Improve Risk Stratification in Aortic Stenosis

    by Ahmed Abdelmohsen Zayed, Michel El Khoury, Bahy Abofrekha, Oluwakorede Akele, Hadi Itani, Omar Khayat, Abdelrahman Abouelnas, Nadim Zaidan, Kevin Schesing

    Background: Traditional echocardiographic assessment of aortic stenosis (AS) using aortic valve area (AVA) may overestimate severity due to pressure recovery phenomena, while subclinical myocardial dysfunction remains undetected despite preserved ejection fraction. This study evaluated whether energy loss index (ELI)—which accounts for pressure recovery—demonstrates superior correlation with global longitudinal strain (GLS), a marker of subclinical myocardial dysfunction, compared to conventional AVA-based classification in patients with moderate-to-severe AS and preserved left ventricular ejection fraction (LVEF). Methods: This retrospective single-center study analyzed 149 patients with moderate-to-severe AS (AVA < 1.5 cm2) and LVEF > 50% from 2015 to 2019. Among 97 patients with severe AS by AVA (2), ELI was calculated using the formula ELI = (AVA × Aa)/(Aa − AVA) ÷ BSA, where Aa represents sinotubular junction cross-sectional area. Patients with ELI ≥ 0.6 cm2/m2 were reclassified as moderate AS. Spearman correlation assessed relationships between AVA, ELI, and GLS. Multivariable linear regression models determined independent predictors of myocardial dysfunction, adjusting for age, body surface area, hypertension, LVEF, and mean pressure gradient. Results: ELI reclassified 28 of 97 patients (29%) from severe to moderate AS. Reclassified patients had significantly better myocardial function, with less impaired GLS (−15.0 ± 3.9% vs. −12.1 ± 5.0%, p = 0.013) and higher LVEF (60.1 ± 6.2% vs. 56.5 ± 9.1%, p = 0.017) compared to non-reclassified patients. In the overall cohort, ELI demonstrated stronger correlation with GLS than AVA (r = −0.307, p = 0.0003 vs. r = −0.209, p = 0.0115). Critically, among patients with severe AS by AVA criteria, ELI maintained significant correlation with GLS (r = −0.443, p = 0.0003) while AVA showed no correlation (r = −0.144, p = 0.159). In multivariable analysis, ELI independently predicted GLS (β = 5.847, 95% CI: 2.85–8.84, p = 0.0002; adjusted R2 = 0.289), whereas AVA did not (β = 2.234, 95% CI: −1.08 to 5.55, p = 0.188; adjusted R2 = 0.234). When both parameters were included simultaneously, only ELI remained significant (p = 0.0024). Conclusions: In this retrospective cohort, ELI-based reclassification identified a subgroup of patients with less severe myocardial dysfunction as measured by GLS and LVEF, and ELI demonstrated superior correlation with subclinical myocardial dysfunction compared to AVA. These findings suggest ELI may provide a more physiologically reflective assessment of hemodynamic burden in AS with preserved LVEF. However, the absence of systematic symptom assessment and clinical outcome data represents critical limitations. Prospective studies with standardized symptom evaluation, longitudinal follow-up, and adjudicated clinical endpoints are required to determine whether ELI-based reclassification improves risk stratification and clinical decision-making before this approach can be recommended for routine practice.

  • Open Access

    Improvement in Right Ventricular Function and Pulmonary Pressures in Patients With Severe Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction Treated With Sacubitril‐Valsartan

    by Bahy Abofrekha, Jennifer Jdaidani, Mahmoud Shadi, Elie Bou Sanayeh, Alaukika Agarwal, Nadim Zaidan, Geurys R. Rojas‐Marte

    Pulmonary hypertension (PH) significantly impacts outcomes in heart failure with preserved ejection fraction (HFpEF), especially with right ventricular dysfunction (RVD), yet effective treatments are limited. This study retrospectively evaluated sacubitril‐valsartan's effects on pulmonary pressures, RV function, and clinical outcomes in 20 severe HFpEF‐PH patients. Significant improvements were observed over a median 397‐day follow‐up. Sacubitril‐valsartan notably reduced RV systolic pressure (RVSP) by 27.50 mmHg ( p < 0.0001) and peak tricuspid regurgitation (TR) velocity by 0.825 m/s ( p < 0.0001). TR severity improved significantly ( p = 0.0426). RV dimensions decreased significantly (basal: p = 0.0083; mid‐cavity: p = 0.0025). RV‐pulmonary arterial coupling (TAPSE/RVSP) improved from 0.27 to 0.47 ( p < 0.0001), and NYHA functional class improved from mean III to II ( p = 0.0164). Systolic blood pressure also decreased by 24.0 mmHg ( p < 0.0001). Diastolic function parameters (E velocity, E/e', LAVI) did not show significant changes. These findings suggest that sacubitril‐valsartan could improve pulmonary pressures, RV dimensions, RV‐PA coupling, TR severity, and functional status in HFpEF‐PH patients, supporting its potential therapeutic role.

  • Open Access

    Association of Kidney Stone Disease With Metabolic Dysfunction Associated Liver Disease and Metabolic Dysfunction Associated Steatohepatitis: A National Inpatient Sample Study

    by Toni Habib, Nadim Zaidan, Karim Jaber, Hachem Araji, Liliane Deeb, George Bonifant, Elie El‐Charabaty, Suzanne El‐Sayegh, Lama Nazzal

    Background: While many studies have identified steatotic liver disease (SLD) as a risk factor for kidney stone disease (KSD), the impact of the severity of steatosis has not been clearly elucidated in the context of other metabolic risk factors for KSD. This cross‐sectional population‐based study of a large inpatient database sought to investigate the association between KSD and SLD.Methods: We queried the National Inpatient Database between 2016 and 2020 to identify patients with urolithiasis as well as patients with SLD, and identify other risk factors for stone disease, such as obesity, type II diabetes, and gout using ICD10 codes. Logistic regression was computed for strength and significance of the relationship between both SLD severity levels and KSD, in univariate and multivariate regression adjusted for patient characteristics and comorbidities burden. All statistical analyses were performed using SAS Enterprise Software 9.4.Results: Odds of being a kidney stone former were significantly higher in patients with MASLD and MASH than in patients without liver injury in the general hospitalized population. Analysis performed in a cohort of hospitalizations that included BMI identifiers showed that this association of both degrees of SLD with KSD was more pronounced than that with diabetes and gout. Finally, comparing both forms of disease severity head‐to‐head, MASLD was found to have a stronger association with KSD than MASH.Conclusion: Patients with SLD were found to have a higher prevalence of KSD. The more pronounced association in MASLD and the lower‐than‐expected contribution of other conditions involving dysregulation of metabolic homeostasis such as gout or diabetes highlights the central role of SLD in KSD pathogenesis.


  • Open Access

    Questionable role of opioids for analgesia in renal colic and its urological interventions

    by Anna Krieger, Nadim Zaidan, Philip Zhao, James F. Borin, David S. Goldfarb

    Objectives: To review the different analgesic modalities and benefits of non‐opioid pain management options as well as their evidence‐based, established superiority, compared to opioid medications.Materials: We review the updated literature about pain management of renal colic, a prevalent and painful urologic condition. Prescribers must know the efficacy, safety and possible ramifications of analgesic selections.Results: Commonly prescribed medications in the United States (US) include non‐steroidal anti‐inflammatory drugs (NSAIDs), acetaminophen, and opioids. In the context of the current epidemic of death from overdoses of opioids in the US, the frequency of opioid prescribing for renal colic is likely excessive, problematic and potentially remediable. We also present analgesic modalities revolving around interventions with peri‐procedural pain management for ureteroscopy and percutaneous nephrolithotomy. After touching on the implications of misguided opioid use, especially in the context of kidney stone disease, and despite the evidence and consensus guidelines supporting NSAIDs in renal colic, current evidence has shown that many clinicians continue to prescribe opioids as first‐line treatment. Finally, we highlight current efforts targeted at the reduction of opioid use and prescription in the setting of provider education and decision aids in curbing misguided opioid use in renal colic.Conclusions: While the evidence against treating kidney stones with opioids is clear, more work is needed to shift current practices to reflect that renal colic is a non‐opioid‐requiring condition.


  • Spontaneous ileitis and postsurgical murine models of enteric hyperoxaluria

    by Karim Jaber, Nadim Zaidan, Melody Ho, Xiaozhong Xiong, Rashmi Mishra, Ambika Nair, Arnav Mishra, Yi Chu, Mohamad Mokadem, Lama Nazzal

    This study is among the first to establish an enteric hyperoxaluria (EH) phenotype in two different and novel mouse models secondary to Roux-en-Y gastric bypass and ileitis. It also elucidates key factors affecting EH using the SAMP1 mice, revealing the significant roles of GI tract inflammation, fat malabsorption, and dietary fat in developing hyperoxaluria.


  • Open Access

    Intubation in Eosinophilic Lung Disease: Predictors, Outcomes, and Characteristics from a National Inpatient Sample Analysis

    by Michel Al Achkar, Nadim Zaidan, Chloe Lahoud, Zaineb Zubair, Jessica Schwartz, Erica Abidor, Chris Kaspar, Halim El Hage

    Background and Objectives: Eosinophilic lung diseases (ELD) encompass disorders with an abnormally high number of polymorphonuclear eosinophils in the lungs. Presentation severity can range from low-grade fever and cough to life-threatening acute respiratory distress syndrome (ARDS). Due to the rarity of these conditions, no large sample studies have been performed to assess the characteristics of patients with pulmonary eosinophilia. Materials and Methods: Patients admitted with a diagnosis of pulmonary eosinophilia between the years 2016 and 2020 were extracted from the largest inpatient US database, the Nationwide Inpatient Sample (NIS). Patients under the age of eighteen and those with diabetic ketoacidosis were excluded. Baseline demographic characteristics and medical comorbidities were evaluated for individuals admitted with pulmonary eosinophilia depending on intubation requirement. The primary outcomes included in-hospital mortality, intubation, and length of stay (LOS). Results: 3784 records were extracted, among which 384 patients required intubation. Patients who required intubation had higher rates of in-hospital mortality (23.9% vs. 1.2% p < 0.0001%) and a significantly more prolonged hospital stay (19 days vs. 6 days p < 0.001) compared to patients who did not need intubation. Factors associated with mortality in the intubated group included increasing age (OR: 1.022, 95% CI 1.002–1.042), duration of intubation superior to 96 h (OR: 2.705, 95% CI 1.235–5.927), and AKI (OR: 2.964, 95% CI 1.637–5.366). Conclusions: Our findings suggest that ELD patients requiring intubation experience significantly higher rates of in-hospital mortality, acute kidney injury, deep venous thrombosis, and ARDS.

  • Opioid use and poisoning in hospitalized patients with chronic kidney disease

    by Nadim Zaidan, Youssef Jalloul, David S. Goldfarb, Hiba Azar, Suzanne El-Sayegh

    Background Identifying factors associated with uncomplicated and complicated opioid use is essential, especially with regard to safety concerns in impaired kidney function. Literature about opioid prescription and their potential complications in patients with different stages of chronic kidney disease (CKD) is scarce. This study describes opioid use and poisoning in hospitalized CKD patients. Methods The National Inpatient Database (NIS) was queried from 2016 to 2020 to identify which patients with known CKD stages were admitted with diagnoses of uncomplicated and complicated opioid use, and opioid poisoning. Patients with end-stage kidney disease receiving any form of renal replacement therapy were excluded. CKD1 served as a reference, and demographic and socio-economic characteristics were accounted for. Logistic regressions were performed to evaluate the relationship between CKD stages and each condition. Results The final cohort included 2,917,404 (14,587,017 weighted) CKD patients, of whom 1.763 ± 0.023% and 1.177 ± 0.016% had uncomplicated and complicated opioid use, respectively. Odds of uncomplicated use were lower with more advanced CKD stages. We observed an increase of complicated use with milder forms of CKD. No differences in odds of complicated opioid use were found when CKD4-5 patients were compared to CKD1. After adjustment, opioid use was found to be the main predictor of poisoning in hospitalized CKD patients. Conclusion Prescribers appear to be more cautious in patients with advanced CKD, with lower odds of being on opioid analgesics in this group. Most CKD patients had higher odds of complicated use, and poisoning was essentially driven by complicated opioid use rather than CKD stage. Graphical abstract

  • Open Access

    Prevalence of Metabolic Syndrome and Its Association with Cardiovascular Outcomes in Hospitalized Patients with Inflammatory Bowel Disease

    by Ryan Njeim, Sai Shanmukha Sreeram Pannala, Nadim Zaidan, Toni Habib, Medha Rajamanuri, Elie Moussa, Liliane Deeb, Suzanne El-Sayegh

    Background: Patients with autoimmune diseases experience a higher burden of metabolic syndrome (MetS) and cardiovascular disease (CVD). There is a paucity of data regarding MetS in patients with inflammatory bowel disease (IBD) and its impact on CVD. In this retrospective study, we aimed to evaluate the prevalence of MetS components in IBD patients, as well as their association with acute coronary syndrome (ACS), heart failure and arrhythmias. Methods: After pooling 5 years of data from the National Inpatient Sample (NIS) Database (2016–2020), we compared traditional cardiovascular risk factors between IBD and non-IBD patients. We then investigated the association between MetS (represented by a calculated metabolic score (CMS) ranging from 0 to 4, based on the presence or absence of hypertension, obesity, dyslipidemia and type II diabetes) and CVD, separately for Crohn’s disease (CD) and ulcerative colitis (UC) patients. Results: The prevalence of the different MetS components was found to be lower in IBD patients compared to non-IBD patients. Comparing CD (n = 806,875) and UC (n = 575,925) identified a higher prevalence of MetS components in UC. Higher CMS was positively associated with ACS and arrhythmias in both CD and UC. This association was evident in heart failure, with the odds ratio increasing from 2.601 for CMS = 1 to 6.290 for CMS = 4 in UC patients and from 2.622 to 5.709 in CD patients. Conclusions: Our study highlights the positive association between traditional components of MetS and CVD in IBD patients. Our findings suggest that chronic inflammation explains only partially the CVD burden in hospitalized IBD patients.


  • Open Access

    The Microbiome and Uremic Solutes

    by Nadim Zaidan, Lama Nazzal

    Uremic retention solutes, especially the protein-bound compounds, are toxic metabolites, difficult to eliminate with progressive renal functional decline. They are of particular interest because these uremic solutes are responsible for the pathogenesis of cardiovascular and chronic kidney diseases. Evidence suggests that the relation between uremic toxins, the microbiome, and its host is altered in patients with chronic kidney disease, with the colon’s motility, epithelial integrity, and absorptive properties also playing an important role. Studies found an alteration of the microbiota composition with differences in species proportion, diversity, and function. Since uremic toxins precursors are generated by the microbiota, multiple therapeutic options are currently being explored to address dysbiosis. While an oral adsorbent can decrease the transport of bacterial metabolites from the intestinal lumen to the blood, dietary measures, supplements (prebiotics, probiotics, and synbiotics), and antibiotics aim to target directly the gut microbiota composition. Innovative approaches, such as the modulation of bacterial enzymes, open new perspectives to decrease the plasma level of uremic toxins.